Could This RSV News Make Moderna a Hot Buy Again?
Moderna's (NASDAQ: MRNA) business isn't in as horrible shape as bearish investors may think. The company, which has made a name for itself for its COVID-19 vaccine, has products in its pipeline that could generate significant revenue in the future beyond just COVID.
One of the most promising is a vaccine candidate for respiratory syncytial virus (RSV). Moderna recently released encouraging results from a trial that could drive some bullishness on the stock. Is now the time to buy shares of Moderna before they potentially climb higher?
On Jan. 17, Moderna announced that its RSV vaccine was highly effective in phase 3 trials in preventing the risk of lower respiratory disease (where there were at least two symptoms) in people aged 60 and over. The rate of efficacy was 83.7%. That's slightly higher than the 82.6% efficacy that GSK reported from its vaccine in October, and well above the 66.7% that rival Pfizer achieved when it announced its trial results a few months earlier in August.
Source Fool.com
